Riskpilot← Back to searchSign inGet full accessPROPHYLAXIA AS
ASActiveOrg 994829750Daugstadvegen 445, 6392 VikebuktMarine aquaculture · NACE 0321Est. 200927 employees
Revenue 2024
NOK 322,8M
+38% vs 2023
EBITDA margin
21.5%
-25% vs 2023
Equity ratio
20.9%
Financial strength
Net profit 2024
NOK 81,9M
+47% vs 2023
| Revenue | NOK 322,8M | +38% |
| EBITDA | NOK 69,4M | -25% |
| Net profit | NOK 81,9M | +47% |
| Total assets | NOK 848M | +39% |
| Equity | NOK 176,9M | +103% |
| Employees | 27 | — |
Legal name
PROPHYLAXIA AS
Org number
994829750
Legal form
Aksjeselskap
NACE code
0321 · Marine aquaculture
Founded
5. desember 2009
Share capital
NOK 135 294
Employees
27 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Forske og utvikle bioteknologiske produkter hovedsaklig til akvanæringen, selge og markedsføre disse, samt å delta i annen næringsvirksomhet med beslektet type aktivitet.
Address
Daugstadvegen 445, 6392 Vikebukt
Email
post@prophylaxia.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 48 356 | 178 320 | 77 061 | 234 717 | 322 794 |
| Staff expenses | −4 925 | −6 728 | −7 621 | −11 269 | −15 975 |
| EBITDA | 13 713 | 50 619 | 13 853 | 92 522 | 69 370 |
| Depreciation & amort. | −1 539 | −1 963 | −2 039 | −1 968 | −7 012 |
| EBIT | 12 174 | 48 656 | 11 814 | 90 554 | 62 358 |
| Net financials | −820 | −919 | −3 481 | −19 124 | 28 679 |
| Profit before tax | 11 354 | 47 737 | 8 333 | 71 429 | 91 037 |
| Tax | 2 271 | 10 403 | 1 814 | 15 735 | 9 091 |
| Net profit | 9 083 | 37 334 | 6 519 | 55 695 | 81 947 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 140 179 | 119 580 | 409 526 | 612 160 | 848 023 |
| Equity | 17 730 | 25 065 | 31 583 | 87 278 | 176 869 |
| Long-term debt | 7 391 | 1 672 | 223 006 | 218 205 | 333 746 |
| Short-term debt | 115 057 | 92 844 | 154 936 | 306 677 | 337 408 |
| Total debt | 122 448 | 94 516 | 377 942 | 524 881 | 671 154 |
EBITDA margin
21.5%
This company
15.8%
Market median
+36% vs market
20202024
Equity ratio
20.9%
This company
38.2%
Market median
-45% vs market
20202024
Return on equity
46.3%
This company
18.4%
Market median
+152% vs market
20202024
Net profit margin
25.4%
This company
8.1%
Market median
+214% vs market
20202024
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20202024
Debt / equity
3.79×
This company
0.62×
Market median
-511% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ØV Chief Executive Officer | Chief Executive Officer | 2017 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2017 | |
| Board of Directors | 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.6% | 66.6% | 2024 | |
| Company | 16.65% | 16.65% | 2024 | |
| Company | 15% | 15% | 2024 | |
| Company | 1.75% | 1.75% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
P & V Holding As
PROPHYLAXIA AS Board members of PROPHYLAXIA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øyvind Våge | Chief Executive Officer | 0 companies |
| Bjørn-Vegard Løvik | Chairman | 0 companies |
| Ivar Gulla | Board of Directors | 0 companies |